^
Association details:
| Biomarker: | RUNX1 mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | BTX-A51 (CDK9 inhibitor, CDK7 inhibitor, p53 stimulant, Casein kinase 1 alpha inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Safety and efficacy of casein kinase 1α and cyclin dependent kinase 7/9 inhibition in patients with relapsed or refractory AML: A first-in-human study of BTX-A51.
Published date:
05/26/2022
Excerpt:
In this FIH study, monotherapy BTX-A51 demonstrated an acceptable safety profile and promising antileukemic activity in pts with heavily pretreated R/R AML. The 21 mg dose administered 3x/wk for 4 wk was identified as the RP2D. RUNX1 mutations were enriched among responders and pts attaining > 50% BM blast reduction.
DOI:
10.1200/JCO.2022.40.16_suppl.7030
Trial ID:
